Development of intravascular targeting hyperthermia using dextran magnetite complex
Project/Area Number |
05557046
|
Research Category |
Grant-in-Aid for Developmental Scientific Research (B)
|
Allocation Type | Single-year Grants |
Research Field |
Radiation science
|
Research Institution | KYOTO UNIVERSITY |
Principal Investigator |
HIRAOKA Masahiro Kyoto Univ.Fac.of Associate Medicine Prof., 医学部, 助教授 (70173218)
|
Co-Investigator(Kenkyū-buntansha) |
NAGAE Hideo Meito Indust.Co.Nagoya Chief Research Institute, 名古屋研究所, 主任研究員
NAGATA Yasushi Kyoto Univ.Fac.of Assist.Medicine Prof., 医学部, 助手 (10228033)
NISHIMURA Yasumasa Kyoto Univ.Fac.of Lecturer Medicine, 医学部, 講師 (00218207)
|
Project Period (FY) |
1993 – 1994
|
Project Status |
Completed (Fiscal Year 1994)
|
Budget Amount *help |
¥7,700,000 (Direct Cost: ¥7,700,000)
Fiscal Year 1994: ¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1993: ¥5,500,000 (Direct Cost: ¥5,500,000)
|
Keywords | Hyperthermia / Intravascular / Embolization / Magnetic Fluid / Dextran Magnetite Complex / 温熱療法 / Hyperthermia / Targeting / Intaarterial / Embolization / Magnetic Fluid / Dextran Magnetic |
Research Abstract |
This is a fundamental study to develop an "intravascular targeting hyperthermia" , in which a deep seated tumor is heated using an intravascularly administered magnetic material together with an externally applied AC magnetic field. As a heat generating material, we employed dextran magnetite complex (DM) , which is a kind of 'magnetic fluid'. The heat production of DM in an AC magnetic field is much higher than previously reported multidomain ferrite particles due to a different mechanism of heat generation. We designed two DM-containing embolic materials, a DM/Lipiodol(]SY.encircledR.[) emulsion and a DM/degradable starch microsphere (DM/DSM) suspension. In vitro experiments showed that the heat generating capacity of DM was not reduced in these preparations. When these materials were injected into the renal arteries of Japanese white rabbits, they achieved selective heating (over 10゚C/10min.) of the embolized kidney following exposure to a 100kHz AC magnetic field of approximately 1
… More
5000 A/m. The average iron concentration in the embolized kidney was 4.9 (]SY.+-.[) 2.4mg Fe/g tissue. A similar experiment with a VX2 tumor transplanted in the liver of a rabbit demonstrated sufficient heating of the tumor. With current composition of DM containing embolic material, DM escapes into systemic circulation and is trapped by reticulo endothelial system (RES) within 6 hours of intraarterial administration. Moreover, an experiment using C3H mouse model revealed that the heat generating capacity of DM is decreased as it is metabolize13EA01 : This is a fundamental study to develop an"intravascular targeting hyperthermia" , in which a deep seated tumor is heated using an intravascularly administered magnetic material together with an externally applied AC magnetic field. As a heat generating material, we employed dextran magnetite complex (DM) , which is a kind of 'magnetic fluid'. The heat production of DM in an AC magnetic field is much higher than previously reported multidomain ferrite particles due to a different mechanism of heat generation. We designed two DM-containing embolic materials, a DM/Lipiodol(]SY.encircledR.[) emulsion and a DM/degradable starch microsphere (DM/DSM) suspension. In vitro experiments showed that the heat generating capacity of DM was not reduced in these preparations. When these materials were injected into the renal arteries of Japanese white rabbits, they achieved selective heating (over 10゚C/10min.) of the embolized kidney following exposure to a 100kHz AC magnetic field of approximately 15000 A/m. The average iron concentration in the embolized kidney was 4.9 (]SY.+-.[) 2.4mg Fe/g tissue. A similar experiment with a VX2 tumor transplanted in the liver of a rabbit demonstrated sufficient heating of the tumor. With current composition of DM containing embolic material, DM escapes into systemic circulation and is trapped by reticulo endothelial system (RES) within 6 hours of intraarterial administration. Moreover, an experime Less
|
Report
(3 results)
Research Products
(14 results)